CLINICAL TRIAL & MOLECULAR BIOMARKER RESEARCH
- Single platform with the capability of integrating clinical, nonclinical, bio samples, NGS, OMICS and more in a comprehensive global repository with dynamic search capabilities across domains.
- Select highly stratified patient cohorts prospectively or retrospectively across clinical studies based on patient history, study type/ compounds, specific molecular biomarkers, treatments, sample and consent availability and results of previous analysis.
- Correlate clinical data and genomic biomarkers tracked prior to or during trial.
- Cross-study search across clinical and nonclinical studies, discovery of signals and viewing of studies from both an efficacy and safety perspective.
Example Use Cases for Xbiom™ Insights:
- Find a cohort of patients who have survived more than 300 days after treatment of Compound X. Patients may be selected across multiple studies. Selected patients for the cohort must be between the ages of 30 and 60 and measurements of certain blood parameters (WBC, RBC) must have been regularly measured during the monitored period. Their bio-samples are available for genomic screening and the patients shall have provided informed consent for use of their bio-samples.
- Identify subjects who have participated in clinical trials for a specific treatment, say of compound X. The subjects of interest are female and only those subjects who have plasma samples that are valid at least until a specific date in the future, say June 1, 2022. The caretakers or biobanks must be shown along with the sample details and identifiers. Only those subjects who have provided samples and consent for its use will be selected.
- Find data sets among participating patients who have displayed BRCA1 and BRCA2 biomarkers and where these female patients have provided consent for genomic screening of their bio-samples. Find the methods used for the original screening and compare their results.
- On studies for compound X, find subjects that have shown concentrations of Interleukin 4 and 5 above xx pg/ml along with demonstrated mutation of YYYY molecular biomarker at position NN.